Balanced news tone
News Sentiment
LEGN sentiment intelligence
Legend Biotech Corp news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
53
Balanced news tone
66 relevant articles
Price is moving more forcefully than the current news tone suggests.
82/100 classification confidence.
directly relevant articles
high-authority source matches
-9.5% over one week, -24.5% over four weeks, trend active, and below fair value.
Lobbying Update: $90,000 of LEGEND BIOTECH CORPORATION lobbying was just disclosed
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
82/100 classification
One-week reaction
-9.5%
Price reacting lower
Trend fit
Trend active
-24.5% over four weeks
Fair value
-35.8%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
14
Neutral
48
Negative
4
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Quiver Quantitative
Direct company coverage
Lobbying Update: $90,000 of LEGEND BIOTECH CORPORATION lobbying was just disclosed
LEGEND BIOTECH CORPORATION (LEGN) disclosed $90,000 in lobbying expenses for Q2 2026, focusing on educating Congress about biotechnology's role in healthcare. Insider trading data shows two sales by the CEO, totaling $169,404, while hedge funds exhibit mixed activity with signifi
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 23:13
- Source
- Quiver Quantitative
Stock Titan
Direct company coverage
Legend Biotech (NASDAQ: LEGN) reports $657M CARVYKTI sales
Legend Biotech (NASDAQ: LEGN) reported preliminary net trade sales of approximately $657 million for CARVYKTI® for the quarter ended June 30, 2026, based on data provided by Janssen. This figure has not been independently verified or audited by Legend Biotech's accountants and is
- Tone
- Positive 61/100
- Event
- Earnings
- Published
- 15 Jul 2026 11:13
- Source
- Stock Titan
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
Investing.com Nigeria
Direct company coverage
JPMorgan resumes Legend Biotech stock coverage with neutral rating By Investing.com
JPMorgan has resumed coverage of Legend Biotech Corp. (NASDAQ: LEGN) with a Neutral rating and a price target of $35.00 for December 2027. The firm acknowledges the strong launch of Legend Biotech's Carvykti but expresses concerns about competitive threats and the unproven potent
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 13 Jul 2026 12:10
- Source
- Investing.com Nigeria
GuruFocus
Direct company coverage
JPMorgan Initiates Coverage of Legend Biotech (LEGN) with Neutra
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 10:50
- Source
- GuruFocus
GuruFocus
Direct company coverage
LEGN Reinstated by JP Morgan -- Rating Set to Neutral
JP Morgan has reinstated Legend Biotech (LEGN) with a Neutral rating and a price target of $35.00, reflecting a cautious outlook despite the stock being significantly undervalued according to GuruFocus's GF Value™. While LEGN shows strong growth potential and momentum, its high f
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 13 Jul 2026 11:41
- Source
- GuruFocus
GuruFocus
Direct company coverage
JPMorgan Initiates Coverage of Legend Biotech (LEGN) with Neutral Outlook
JPMorgan has initiated coverage of Legend Biotech (LEGN) with a Neutral rating and a $35 price target, citing a strong launch for its CAR T-cell therapy Carvykti but expressing caution regarding competitive pressures. The company, with a market cap of $5.24 billion and a GF Score
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 13 Jul 2026 10:41
- Source
- GuruFocus
DirectorsTalk Interviews
Direct company coverage
Legend Biotech Corporation (LEGN) Stock Analysis: A Promising 111% Potential Upside in the Biotech Sector
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 13 Jul 2026 09:23
- Source
- DirectorsTalk Interviews
MarketBeat
Direct company coverage
Legend Biotech (LEGN) Short Interest & Short Float | Updated Jul 2026
As of June 30, 2026, Legend Biotech (LEGN) had a short interest of 13.11 million shares, representing 7.06% of the public float. This was a 0.96% increase from the previous report, with a short interest ratio of 4.2 days to cover. The article provides a detailed historical overvi
- Tone
- Negative 37/100
- Event
- Market update
- Published
- 10 Jul 2026 07:10
- Source
- MarketBeat
www.marketscreener.com
Direct company coverage
RBC Capital Adjusts Legend Biotech Price Target to $63 From $64, Maintains Outperform Rating
RBC Capital has revised its price target for Legend Biotech (NASDAQ: LEGN) to $63, down from $64, while reaffirming its "Outperform" rating on the stock. This adjustment comes amidst recent news regarding the company's financial activities and clinical trial data. Legend Biotech
- Tone
- Positive 58/100
- Event
- Analyst action
- Published
- 07 Jul 2026 12:11
- Source
- www.marketscreener.com
Ad-hoc-news.de
Direct company coverage
Legend Biotech Corp highlights cell therapy pipeline as shares trade on Nasdaq
Legend Biotech Corp is advancing its cell therapy pipeline, focusing on oncology and immunology treatments, as its shares trade on Nasdaq. The company specializes in autologous cell therapy platforms and is recognized for its investigational therapies in hematologic malignancies
- Tone
- Positive 66/100
- Event
- Regulatory and legal
- Published
- 03 Jul 2026 22:13
- Source
- Ad-hoc-news.de
Stock Titan
Direct company coverage
Legend Biotech (LEGN) CEO Ying Huang makes charitable gift of 3,382 shares
Legend Biotech Corp's CEO and director, Ying Huang, reported a charitable gift of 3,382 Ordinary Shares to a charitable organization. This transaction, filed as a Form 4, involved no cash consideration and leaves Huang with a direct ownership of 238,490 Ordinary Shares. The compa
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 03 Jul 2026 18:10
- Source
- Stock Titan
Stock Titan
Direct company coverage
Legend Biotech (LEGN) director sells 6,000 shares at $14.80 each in open-market trade
Legend Biotech Corp director Casey Patrick John sold 6,000 Ordinary Shares in an open-market transaction at $14.80 per share, or $29.60 per American Depositary Share (ADS). After the sale, Mr. John directly holds 48,604 Ordinary Shares, indicating a continued significant equity s
- Tone
- Negative 29/100
- Event
- Market update
- Published
- 03 Jul 2026 18:10
- Source
- Stock Titan
GuruFocus
Direct company coverage
Insider Sell Alert: Patrick Casey Sells 6,000 Shares of Legend B
Patrick Casey, a Director at Legend Biotech Corp (LEGN), sold 6,000 shares of the company on June 30, 2026, reducing his holdings to 48,604 shares. This transaction follows a period of no insider buys and three insider sells over the past year for Legend Biotech. The stock is cur
- Tone
- Negative 29/100
- Event
- Market update
- Published
- 02 Jul 2026 23:10
- Source
- GuruFocus
Finviz
Direct company coverage
LEGN - Legend Biotech Corp ADR Earnings
This article provides detailed financial data and performance metrics for Legend Biotech Corp ADR (LEGN). It includes key financial figures like market cap, income, sales, EPS, and various ratios, alongside stock performance over different periods. The data also covers ownership
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 02 Jul 2026 16:39
- Source
- Finviz
TradingView
Direct company coverage
Legend Biotech Corporation Stock 12‑Month Price Target Cut to $55.21, Implies 85% Upside
Legend Biotech Corporation's average 12-month stock price target has been lowered from $56.13 to $55.21 by 14 analysts, with forecasts ranging from $27 to $86 per share. This new target implies an 85% potential upside based on the July 1 closing price. Despite the target cut, the
- Tone
- Positive 64/100
- Event
- Analyst action
- Published
- 02 Jul 2026 16:10
- Source
- TradingView
Finviz
Direct company coverage
LEGN - Legend Biotech Corp ADR Options
This page provides a detailed financial overview of Legend Biotech Corp (LEGN), including its stock performance, key financial metrics, insider and institutional ownership, and analyst recommendations. As of July 2nd, the stock closed at $29.91, showing a slight increase. The dat
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 02 Jul 2026 15:40
- Source
- Finviz
Investing.com Nigeria
Direct company coverage
Form 144 Legend Biotech Corp For: 30 June By Investing.com
This article reports on the filing of Form 144 by Legend Biotech Corp for the period ending June 30. It provides financial market data including indices, commodities, bonds, and shares, along with a list of trending stocks and recent market movers. The article is a brief announce
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 15:12
- Source
- Investing.com Nigeria
Stock Titan
Direct company coverage
Form 144 Proposed ADS Sale (NASDAQ: LEGN)
A Form 144 filing indicates a proposed sale of 3,000 American Depositary Shares (ADS) of Legend Biotech Corp (NASDAQ: LEGN) through Fidelity Brokerage Services LLC, valued at $88,800. The filing also details multiple past restricted stock vesting events totaling 3,000 ADS between
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 14:38
- Source
- Stock Titan
Investing.com South Africa
Direct company coverage
Form 4 Legend Biotech Corp For: 29 June By Investing.com
This article announces the filing of Form 4 for Legend Biotech Corp for June 29, as reported by Investing.com. It is a brief administrative notice primarily serving to disseminate this financial filing information. The content primarily consists of market data, trending stocks, a
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 03:10
- Source
- Investing.com South Africa
Stock Titan
Direct company coverage
Legend Biotech (NASDAQ: LEGN) CEO disposes shares to cover RSU tax
Legend Biotech Corp's CEO, Ying Huang, reported the disposition of 5,566 ordinary shares on June 25, 2026, at a weighted average price of $14.78 per share. This transaction was non-discretionary and solely to cover withholding tax obligations upon the vesting of restricted share
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 03:10
- Source
- Stock Titan
TradingView
Direct company coverage
Price to sales forward of Legend Biotech Corporation – NASDAQ:LEGN
This article displays the "Price to sales forward" metric for Legend Biotech Corporation (NASDAQ: LEGN) on TradingView. It provides market data and financial information for the company, accessible through the TradingView platform. The page shows that the market was closed at the
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 02:39
- Source
- TradingView
TradingView
Direct company coverage
Legend Biotech Corp. Sponsored ADR Actuals & Estimates (NASDAQ:LEGN)
This page provides an overview of Legend Biotech Corporation's financial actuals and estimates, including reported data and analyst projections for income statements, balance sheets, cash flow, and valuation metrics. Users can compare actual results with average, high, and low es
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 Jun 2026 01:10
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to EBIT forward of Legend Biotech Corporation – NASDAQ:LEGN
This article displays the "Enterprise value to EBIT forward" metric for Legend Biotech Corporation (NASDAQ: LEGN) on TradingView. It indicates that the market was closed with no trades at the time of the data capture. The content is primarily a screenshot or data display from the
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 22:11
- Source
- TradingView
Stock Titan
Direct company coverage
LEGN (NASDAQ) notice: Director/entity proposes sale of 2,783 ADS
Legend Biotech Corp (LEGN) has filed a Form 144 proposing the sale of 2,783 American Depositary Shares (ADS) linked to a Restricted Stock Vesting event on June 22, 2026. The filing indicates a value of $79,016.88 and mentions execution through Fidelity Brokerage Services LLC. It
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 19:11
- Source
- Stock Titan
Kavout | AI
Direct company coverage
What Did the Recent CARVYKTI Data Reveal About Its Potential
Legend Biotech's CARVYKTI demonstrates strong efficacy and safety for multiple myeloma, with recent data supporting its use earlier in treatment. The company reported a significant surge in Q1 2026 sales, driven by global expansion and improved manufacturing efficiency, positioni
- Tone
- Positive 92/100
- Event
- Market update
- Published
- 26 Jun 2026 09:10
- Source
- Kavout | AI
TradingView
Direct company coverage
Enterprise value to revenue forward of Legend Biotech Corporation – NASDAQ:LEGN
This article from TradingView is a placeholder or an incomplete page focusing on the "Enterprise value to revenue forward" metric for Legend Biotech Corporation (NASDAQ:LEGN). It displays basic company information and navigation links for financial data, news, and community secti
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Jun 2026 23:10
- Source
- TradingView
TradingView
Direct company coverage
Price to book forward of Legend Biotech Corporation – NASDAQ:LEGN
The article provides financial data for Legend Biotech Corporation (NASDAQ: LEGN), specifically focusing on its Price to Book Forward metric. It displays the current value, change, and percentage change for this financial indicator. The content appears to be a snapshot from a fin
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jun 2026 21:09
- Source
- TradingView
Market source
Direct company coverage
Legend Biotech Corporation (LEGN) Price Target Raised to $49 on LB5006 Clinical Progress
UBS has raised its price target for Legend Biotech Corporation (LEGN) to $49, reiterating a Buy rating, due to promising early clinical findings for its LB5006 program. Additionally, the company reported positive initial clinical proof-of-concept results for LB2501, an investigat
- Tone
- Positive 70/100
- Event
- Analyst action
- Published
- 25 Jun 2026 13:09
- Source
- Market source
Wilson Sonsini
Direct company coverage
Firm Advises Underwriters on Legend Biotech’s Public Offering
Wilson Sonsini Goodrich & Rosati advised the underwriters in Legend Biotech Corporation's recent underwritten public offering. Legend Biotech priced 7,700,000 American Depositary Shares at $29.35 per ADS, raising approximately $226 million before deductions. The underwriters also
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 24 Jun 2026 19:40
- Source
- Wilson Sonsini